文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者由阿柏西普转换为法瑞西单抗后房水细胞因子分析

Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

本研究前瞻性纳入54例接受阿柏西普按治疗-延长方案治疗的nAMD患者,转换为法瑞西单抗后检测房水细胞因子及临床指标。转换后渗出性改变改善28眼、稳定8眼、恶化18眼;Ang-2显著下降,PlGF显著升高,VEGF-A多低于检测灵敏度;BCVA、CRT、CCT变化无统计学显著差异。作者认为转换可能不仅抑制VEGF-A还抑制Ang-2并减少渗出性改变。

要点

  • 由阿柏西普转换为法瑞西单抗后,52%患眼渗出性改变改善,33%恶化。
  • 房水Ang-2由23.8±23.5 pg/mL降至16.4±21.9 pg/mL(P<0.001)。
  • 房水PlGF由0.86±0.85 pg/mL升至1.72±1.39 pg/mL(P<0.001)。

核心结论

  • 作者认为,nAMD患者由阿柏西普转换为法瑞西单抗可能不仅抑制VEGF-A,还抑制Ang-2并减少渗出性改变。

研究设计与样本

  • 前瞻性研究纳入54例(54眼)接受阿柏西普按治疗-延长方案治疗的AMD患者,转换为法瑞西单抗。
  • 转换前后采集房水,检测Ang-2、PlGF和VEGF-A水平,并用光学相干断层扫描分析BCVA、CRT、CCT和渗出状态。

主要发现

  • 转换后渗出性改变改善28眼(52%)、稳定8眼(15%)、恶化18眼(33%)。
  • BCVA由0.27±0.31变为0.26±0.29(P=0.46),CRT由306.2±147.5 µm降至278.6±100.4 µm(P=0.11),CCT由189.5±92.8 µm变为186.8±93.9 µm(P=0.21)。
  • VEGF-A水平在转换前后许多病例中低于检测灵敏度。
  • Ang-2由23.8±23.5 pg/mL显著降至16.4±21.9 pg/mL(P<0.001),PlGF由0.86±0.85 pg/mL显著升至1.72±1.39 pg/mL(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the changes in aqueous humor cytokine levels and clinical outcomes of switching from aflibercept to faricimab in eyes with neovascular age-related macular degeneration (nAMD). METHODS: Fifty-four eyes of 54 patients with AMD undergoing treatment with aflibercept under a treat-and-extend (TAE) regimen were switched to faricimab and studied prospectively. Best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution), central retinal thickness (CRT), central choroidal thickness (CCT), and exudative status were analyzed using optical coherence tomography. Aqueous humor was collected before and after the switch, and angiopoietin-2 (Ang-2), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) A levels were measured. RESULTS: After switching from aflibercept to faricimab, exudative changes improved in 28 eyes (52%), remained stable in eight eyes (15%), and worsened in 18 eyes (33%). BCVA changed from 0.27 ± 0.31 to 0.26 ± 0.29 (P = 0.46), CRT decreased from 306.2 ± 147.5 µm to 278.6 ± 100.4 µm (P = 0.11), and CCT changed from 189.5 ± 92.8 µm to 186.8 ± 93.9 µm (P = 0.21). VEGF-A levels were below the detection sensitivity in many cases throughout the pre- and post-switching periods. Ang-2 significantly decreased from 23.8 ± 23.5 pg/mL to 16.4 ± 21.9 pg/mL (P < 0.001), and PlGF significantly increased from 0.86 ± 0.85 pg/mL to 1.72 ± 1.39 pg/mL (P < 0.001). CONCLUSIONS: Switching from aflibercept to faricimab in patients with nAMD may not only suppress VEGF-A but also Ang-2 and reduce exudative changes.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Todoroki T, Takeuchi J, Ota H, et al. Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab. Invest Ophthalmol Vis Sci. 2024. PMID: 39250120. doi:10.1167/iovs.65.11.15

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。